186 related articles for article (PubMed ID: 29780899)
1. Perspectives on the evolving state of the art management of gastrointestinal stromal tumours.
Szucs Z; Jones RL
Transl Gastroenterol Hepatol; 2018; 3():21. PubMed ID: 29780899
[TBL] [Abstract][Full Text] [Related]
2. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.
Szucs Z; Thway K; Fisher C; Bulusu R; Constantinidou A; Benson C; van der Graaf WT; Jones RL
Future Oncol; 2017 Jan; 13(1):93-107. PubMed ID: 27600498
[TBL] [Abstract][Full Text] [Related]
3. An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST).
Nannini M; Biasco G; Astolfi A; Pantaleo MA
J Med Genet; 2013 Oct; 50(10):653-61. PubMed ID: 23833252
[TBL] [Abstract][Full Text] [Related]
4. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.
Boikos SA; Pappo AS; Killian JK; LaQuaglia MP; Weldon CB; George S; Trent JC; von Mehren M; Wright JA; Schiffman JD; Raygada M; Pacak K; Meltzer PS; Miettinen MM; Stratakis C; Janeway KA; Helman LJ
JAMA Oncol; 2016 Jul; 2(7):922-8. PubMed ID: 27011036
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
Huss S; Pasternack H; Ihle MA; Merkelbach-Bruse S; Heitkötter B; Hartmann W; Trautmann M; Gevensleben H; Büttner R; Schildhaus HU; Wardelmann E
Hum Pathol; 2017 Apr; 62():206-214. PubMed ID: 28159677
[TBL] [Abstract][Full Text] [Related]
6. [Wild-type gastroinestinal stromal tumors].
Djerouni M; Dumont SN
Bull Cancer; 2020 Apr; 107(4):499-505. PubMed ID: 32063345
[TBL] [Abstract][Full Text] [Related]
7. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
Agaimy A; Terracciano LM; Dirnhofer S; Tornillo L; Foerster A; Hartmann A; Bihl MP
J Clin Pathol; 2009 Jul; 62(7):613-6. PubMed ID: 19561230
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
[TBL] [Abstract][Full Text] [Related]
9. Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors.
Neppala P; Banerjee S; Fanta PT; Yerba M; Porras KA; Burgoyne AM; Sicklick JK
Cancer Metastasis Rev; 2019 Sep; 38(3):525-535. PubMed ID: 31773431
[TBL] [Abstract][Full Text] [Related]
10. Approach to wild-type gastrointestinal stromal tumors.
Kays JK; Sohn JD; Kim BJ; Goze K; Koniaris LG
Transl Gastroenterol Hepatol; 2018; 3():92. PubMed ID: 30603728
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal Stromal Tumours of the Rectum - Evaluating the National Registry Data with Respect to its Use in Clinical Practice.
Svatoň R; Kala Z; Kysela P; Procházka V; Eid M; Andrašina T; Poredská K; Strenková J; Chloupková R; Kunovsky L
Klin Onkol; 2019; 32(2):117-123. PubMed ID: 30995851
[TBL] [Abstract][Full Text] [Related]
12. Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents.
Ricci R; Martini M; Ravegnini G; Cenci T; Milione M; Lanza P; Pierconti F; Santini D; Angelini S; Biondi A; Rosa F; Alfieri S; Clemente G; Persiani R; Cassano A; Pantaleo MA; Larocca LM
Clin Epigenetics; 2019 Jan; 11(1):2. PubMed ID: 30616628
[TBL] [Abstract][Full Text] [Related]
13. Succinate dehydrogenase-deficient gastrointestinal stromal tumors.
Wang YM; Gu ML; Ji F
World J Gastroenterol; 2015 Feb; 21(8):2303-14. PubMed ID: 25741136
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal Stromal Tumors: The GIST of Precision Medicine.
Mei L; Smith SC; Faber AC; Trent J; Grossman SR; Stratakis CA; Boikos SA
Trends Cancer; 2018 Jan; 4(1):74-91. PubMed ID: 29413424
[TBL] [Abstract][Full Text] [Related]
15. The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST).
Nannini M; Urbini M; Astolfi A; Biasco G; Pantaleo MA
J Transl Med; 2017 May; 15(1):113. PubMed ID: 28535771
[TBL] [Abstract][Full Text] [Related]
16. Succinate dehydrogenase deficiency in a PDGFRA mutated GIST.
Belinsky MG; Cai KQ; Zhou Y; Luo B; Pei J; Rink L; von Mehren M
BMC Cancer; 2017 Aug; 17(1):512. PubMed ID: 28768491
[TBL] [Abstract][Full Text] [Related]
17. An immunohistochemical study of potential diagnostic and therapeutic biomarkers of wild-type gastrointestinal stromal tumours.
Wong NA; Wingate J; Gradhand E
Histopathology; 2015 Sep; 67(3):378-85. PubMed ID: 25659413
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
19. Current research and treatment for gastrointestinal stromal tumors.
Lim KT; Tan KY
World J Gastroenterol; 2017 Jul; 23(27):4856-4866. PubMed ID: 28785140
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal stromal tumours: from KIT to succinate dehydrogenase.
Doyle LA; Hornick JL
Histopathology; 2014 Jan; 64(1):53-67. PubMed ID: 24117705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
